Leerink cuts target for Dexcom stock from USD 94 to USD 87

Published on 10/28/2026 at 05:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.31 billion, up 13.1 percent year over year. Dexcom stock reports third-quarter results on October 29, 2026.

Analyst revision and earnings setup

Leerink Partners set a USD 87.00 target after cutting it from USD 94.00 on October 26, 2026.
Second-quarter revenue reached USD 1.31 billion, up 13.1 percent year over year.
Dexcom had a USD 29.6 billion market capitalization as of October 27, 2026.

Dexcom Inc., US2521311074, Illustration mit AI erstellt.

Dexcom Inc. (ISIN US2521311074) is heading into its October 29 results after Leerink Partners cut its target from USD 94.00 to USD 87.00 on October 26, 2026, according to MarketScreener. The revision puts the upcoming report at the center of the stock's near-term valuation debate.

Revenue sets the earnings baseline

Dexcom reported USD 1.31 billion in revenue for the second quarter of 2026, compared with USD 1.16 billion a year earlier. That represents 13.1 percent year-over-year growth, while net income rose to USD 249.1 million from USD 179.8 million, according to Markets Insider.

The standardized second-quarter figures show diluted earnings per share of USD 0.64, while earnings-history data put adjusted earnings per share at USD 0.70 against a USD 0.61 consensus estimate. The comparison matters because the next report will test whether growth is holding as expectations reset.

What does the target cut change?

Leerink's move lowers the target by USD 7.00, or 7.45 percent from USD 94.00. Its new USD 87.00 target remains above the USD 78.57 Nasdaq close cited in the October 26 market coverage, but the cut signals a more cautious near-term valuation frame.

Three dates shape the setup

MarketScreener's Dexcom chronology records RBC raising its target from USD 90.00 to USD 105.00 on October 1, 2026, Mizuho lifting its target from USD 95.00 to USD 100.00 on October 13, 2026, and Leerink cutting its target from USD 94.00 to USD 87.00 on October 26, 2026.

Next reporting date

Dexcom plans to release third-quarter 2026 results after the market close on October 29, 2026, followed by a conference call at 4:30 p.m. ET, the company said in its October 7, 2026 investor-relations release at Dexcom.

Valuation before the report

Dexcom had a market capitalization of USD 29.6 billion as of October 27, 2026. Its 52-week range was USD 54.11 to USD 92.59, placing the stock below its yearly high as the company approaches the earnings release.